Key Developments: StemCells Inc (STEM.PH)

STEM.PH on Philadelphia Stock Exchange

0.41USD
28 Aug 2015
Change (% chg)

$0.02 (+5.99%)
Prev Close
$0.39
Open
$0.41
Day's High
$0.41
Day's Low
$0.41
Volume
200
Avg. Vol
761
52-wk High
$1.53
52-wk Low
$0.38

Search Stocks

Latest Key Developments (Source: Significant Developments)

StemCells Inc announces closing of $25 million public offering
Wednesday, 29 Apr 2015 04:05pm EDT 

StemCells:Closes its previously announced offering of common stock and warrants.Company sold a total of 35,715,000 shares and warrants to acquire 26,786,250 shares of common stock at a public offering price of $0.70 per unit for a fixed combination of one share of common stock and a warrant to purchase three-quarters of a share of common stock.Company also issued warrants to purchase an additional 4,017,938 shares of common stock pursuant to the exercise of the underwriters' option to acquire additional warrants to cover over-allotments.Company received total proceeds, net of offering expenses, underwriting discounts and commissions, of about $23.35 mln.Warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years from the date of issuance.If the warrants are exercised in full, StemCells, Inc. will receive additional proceeds of approximately $26.2 million.Underwriters have a 30-day option to purchase up to an additional 5,357,250 shares of common stock to cover over-allotments.Maxim Group LLC acted as sole book-running manager and Chardan Capital Markets, LLC acted as co-manager for the offering.Meyers Associates, L.P. and IFS Securities, Inc. acted as financial advisors for the offering.  Full Article

StemCells announces pricing of public offering to raise $25 million
Friday, 24 Apr 2015 09:25am EDT 

StemCells:Prices an underwritten public offering of common stock and warrants with a public offering price of $0.70 for a fixed combination of one share of common stock and a warrant to purchase three-quarters of a share of common stock.Warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years from the date of issuance.Expects to receive gross proceeds of about $25.0 mln, before deducting underwriting discounts and commissions and other estimated offering expenses.Company has also granted the underwriters a 30 day option to purchase up to an additional 5,357,250 shares of common stock and/or warrants to purchase up to an additional 4,017,938 shares of common stock to cover over-allotments, if any.Offering is expected to close on or about April 29, 2015, subject to customary closing conditions.Maxim Group LLC is acting as sole book-running manager and Chardan Capital Markets is acting as co-manager for the offering.  Full Article

StemCells Inc appoints Ian Massey as President and Chief Operating Officer
Tuesday, 24 Mar 2015 10:34am EDT 

StemCells Inc:Says Ian Massey, D. Phil., has joined its executive team as President and Chief Operating Officer, effective March 23.Says in this new role, Massey has direct responsibility for all aspects of the Company's research and development, manufacturing, regulatory affairs, and quality assurance activities.  Full Article

TAKARA BIO to acquire stem cell research product related assets from StemCells
Monday, 10 Nov 2014 01:00am EST 

TAKARA BIO INC:To acquire stem cell research product related assets including intellectual properties, from StemCells Inc.To start manufacture and sale of cell research product from Jan. 2015.  Full Article

StemCells Inc initiates phase II clinical trial in Cervical Spinal Cord Injury
Tuesday, 7 Oct 2014 08:00am EDT 

StemCells Inc:Says it has initiated its Pathway Study, a Phase II proof of concept clinical trial using its HuCNS-SC platform of human neural stem cells for the treatment of cervical spinal cord injury (SCI).Says the trial will be conducted as a randomized, controlled, single-blind study and efficacy will be primarily measured by assessing motor function according to the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).Says the primary efficacy outcome will focus on change in upper extremity strength as measured in the hands, arms, and shoulders.Says the trial will follow the patients for one year from the time of enrollment.  Full Article

StemCells Inc announces closing of $20 mln offering
Friday, 18 Jul 2014 01:40pm EDT 

StemCells Inc:Announced that it has closed its previously announced offering of common stock and short term warrants.Says it sold a total of 11,299,435 units to two well recognized institutional biotechnology investors and received total proceeds, net of offering expenses and placement agent fees, of about $18.7 million.Each unit consists of one share of common stock and a warrant to purchase 0.85 of a share of common stock at a price of $1.77 per unit.Warrants will first be exercisable six months from the date of issuance at an initial exercise price of $2.17 per share.Warrants will expire at the close of business on Aug. 17, 2015.Ascendiant Capital Markets, LLC acted as financial advisor and placement agent for the offering.  Full Article

StemCells Inc announces proposed $20 mln offering
Tuesday, 15 Jul 2014 08:00am EDT 

StemCells Inc:Intent to offer and sell 11,299,435 shares of common stock and short term warrants for purchase of up to 9,604,520 additional shares of common stock to two well recognized institutional biotechnology investors.Subject to market and other conditions, for gross proceeds of $20 mln, before deducting placement fees and other offering expenses.Intends to use net proceeds of the offering for general corporate purposes, including working capital, product development and capital expenditures.Common stock and warrants will be sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.85 of a share of common stock at an offering price of $1.77 per unit.Warrants will first be exercisable six months from the date of issuance at an initial exercise price of $2.17 per share.Warrants will expire at the close of business on the date that is 13 months from the date of issuance.Expected to close on or before July 18.Ascendiant Capital Markets, LLC is acting as financial advisor and placement agent for the offering.  Full Article

StemCells Inc announces interim results in Phase I/II Dry AMD Trial
Thursday, 19 Jun 2014 08:00am EDT 

StemCells Inc:Says interim results show improvement in visual function and slowing of disease progression in phase I/II Dry AMD Trial.Reports positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SChuman neural stem cell platform in dry age-related macular degeneration (AMD).Interim trial results show a 65 pct reduction in the rate of geographic atrophy (GA) in the study eye when compared to the expected natural history of the disease as well as a 70 pct reduction in the rate of GA when compared to the control eye.GA is the progressive loss of two important retinal tissue layers, the photoreceptors and the retinal pigmented epithelium.This degeneration is the cause of vision loss in dry AMD.  Full Article

StemCells Inc expands phase I/II spinal cord injury trial to north america
Friday, 10 Jan 2014 08:00am EST 

StemCells Inc:Says a team at the University of Calgary successfully transplanted its first subject in the company's Phase I/II clinical trial in chronic spinal cord injury, with the company's HuCNS-SC human neural stem cells.Says the ninth subject to enroll in the trial, which was initiated in Switzerland, is the first spinal cord injury patient to have undergone transplantation in North America.Says this expansion accelerates the current trial, which should complete enrollment of the remaining three patients this quarter and pave the way for a controlled Phase II efficacy study that StemCells plans to initiate mid-year.  Full Article

StemCells Inc Appoints New Chief Financial Officer
Thursday, 14 Nov 2013 09:00am EST 

StemCells, Inc announced that Greg Schiffman will join its executive team as Chief Financial Officer and Executive Vice President of Finance, effective January 1, 2014. In his new role, Mr. Schiffman will be responsible for all aspects of the Company's financing activities, financial reporting and controls, corporate communications, and investor relations.  Full Article

Search Stocks